BEIJING and BRIDGEWATER, NJ, February 22, 2021 / PRNewswire / – Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, has announced a collaboration with the International Diabetes Federation (IDF) to support its global efforts to advance diabetes care and prevention worldwide. This collaboration offers the opportunity to support future initiatives such as medical education through the IDF School of Diabetes and to become the first partner in the introduction of the IDF WeChat platform China. This partnership also offers the opportunity to participate in advocacy initiatives such as World Diabetes Day and the 100th Anniversary of Insulin. “Gan & Lee’s collaboration with IDF provides an opportunity to support global outreach and advocacy initiatives to improve the lives of people with diabetes.” said Kai Du, CEO of Gan & Lee Pharmaceuticals, Chairman of Gan & Lee USA Group.
Diabetes care is multidimensional due to complex interactions between environmental, lifestyle, clinical and genetic factors. These unique complications, as well as access to ongoing care, training, and medication have a major impact on clinical progression. According to the latest edition of the IDF Diabetes Atlas, approximately 463 million adults (20-79 years of age) were living with diabetes in 2019, and that number is projected to rise to 700 million by 2045. An additional 1 in 2 people with diabetes in 2019 were undiagnosed1. Gan & Lee understands the importance of supporting online educational resources and advocacy initiatives for people affected by diabetes. “The International Diabetes Federation is pleased to have Gan & Lee as partners in support of our global awareness, advocacy and education initiatives. In a year marking the 100th anniversary of the discovery of insulin, coordinated and collaborative efforts to bring about a Ensuring affordable and uninterrupted care Education for everyone living with diabetes, regardless of where they live or economic situation, is more important than ever. “ said Prof. Andrew Boulton, President of the International Diabetes Federation.
About Gan & Lee
Gan & Lee successfully developed the first Chinese biosynthetic human insulin. The company has commercialized five recombinant insulin analogs in China including long-acting glargine injection (basaline®), fast-acting lispro injection (prandilin®), fast-acting aspartic injection (Rapilin™), mixed protamine-zinc-lispro injection (25R) (prandiline®25), aspart 30 injection (Rapilin™30), reusable insulin injection pen (GanleePen™) and disposable needle (Ganlee Fine™). Contact us at investorrelations@ganlee.us.
References
1st International Diabetes Federation. IDF Diabetes Atlas, 9th edition 2019. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf
Media contacts:
Gina Antonucci
888-288-5395
investorrelations@ganlee.us
View original content: http: //www.prnewswire.com/news-releases/gan–lee-announces-new-partnership-with-international-diabetes-federation-301232292.html
SOURCE Gan & Lee Pharmaceuticals Co., Ltd.
